Business
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
Not for distribution to U.S. news wire services or dissemination in the United States WINNI...
About this update from Kane Biotech Inc.
[{"type":"text","content":"Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results\n\n\n\n\n Not for distribution to U.S. news wire services or dissemination in the United States\n \n\n\n WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that today it has completed its previously announced conversion (the “Transaction”) of an unsecured demand loan of $1 million from an insider of the Company into a $1 million principal amount 3% unsecured convertible debenture that is due on June 26, 2030 (the “Debenture”).\n \n\n For further details on the terms of the Debenture, see the press release issued by the Company on June 18, 2025.\n \n\n The closing of the Transaction remains subject to the final approval of the TSX Venture Exchange.\n \n\n The Company also announces that at its Annual and Special Meeting of Shareholders held on June 25, 2025, all Resolutions were voted 98% or higher in favour including the election of three new board directors, Ms. Anne Greven, Mr. Shameze Rampertab and Dr. David Kideckel, and three existing directors, Mr. Philip Renaud, Dr. John Coleman and Dr. Robert Huizinga.\n \n\n\n About Kane Biotech\n \n\n\n Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve™ addresses both biofilms and wound bacteria.\n \n\n\n For more information:\n \n\n\n\n\n\n Dr. Robert Huizinga\n \n\n Interim CEO\n \n Kane Biotech Inc\n \n\n [email protected]\n \n\n (780) 970-1100\n \n\n\n\n\n Ray Dupuis\n \n\n Chief Financial Officer\n \n Kane Biotech Inc\n \n\n [email protected]\n \n\n (204) 298-2200\n \n\n\n\n\n\n\n\n\n\n\n\n\n Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n \n\n\n\n Caution Regarding Forward-Looking Information\n \n\n\n This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under app...